

Clinical paper

Outcomes of patients undergoing early sepsis resuscitation for cryptic shock compared with overt shock[☆]

Michael A. Puskarich^a, Stephen Trzeciak^c, Nathan I. Shapiro^d, Alan C. Heffner^a, Jeffrey A. Kline^a, Alan E. Jones^{a,b,*}, On behalf of the Emergency Medicine Shock Research Network (EMSHOCKNET)

^a Department of Emergency Medicine, Carolinas Medical Center, Charlotte, NC, United States

^b Department of Emergency Medicine, University of Mississippi Medical Center, Jackson, MS, United States

^c Departments of Medicine, Division of Critical Care Medicine and Emergency Medicine, Cooper University Hospital, Camden, NJ, United States

^d Department of Emergency Medicine and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA, United States

ARTICLE INFO

Article history:

Received 4 March 2011

Received in revised form 5 May 2011

Accepted 1 June 2011

Keywords:

Sepsis

Septic shock

Lactate

Resuscitation

Mortality

ABSTRACT

Introduction: We sought to compare the outcomes of patients with cryptic versus overt shock treated with an emergency department (ED) based early sepsis resuscitation protocol.

Methods: Pre-planned secondary analysis of a large, multicenter ED-based randomized controlled trial of early sepsis resuscitation. All subjects were treated with a quantitative resuscitation protocol in the ED targeting 3 physiological variables: central venous pressure, mean arterial pressure and either central venous oxygen saturation or lactate clearance. The study protocol was continued until all endpoints were achieved or a maximum of 6 h. Outcomes data of patients who were enrolled with a lactate >4 mmol/L and normotension (cryptic shock) were compared to those enrolled with sustained hypotension after fluid challenge (overt shock). The primary outcome was in-hospital mortality.

Results: A total of 300 subjects were enrolled, 53 in the cryptic shock group and 247 in the overt shock group. The demographics and baseline characteristics were similar between the groups. The primary endpoint of in-hospital mortality was observed in 11/53 (20%, 95% CI 11–34) in the cryptic shock group and 48/247 (19%, 95% CI 15–25) in the overt shock group, difference of 1% (95% CI –10 to 14; log rank test $p=0.81$).

Conclusion: Severe sepsis with cryptic shock carries a mortality rate not significantly different from that of overt septic shock. These data suggest the need for early aggressive screening for and treatment of patients with an elevated serum lactate in the absence of hypotension.

© 2011 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Severe sepsis hospitalizations have doubled over the last decade resulting in at least 750,000 persons affected annually in the United States (US).^{1,2} Estimates suggest that 500,000 patients with severe sepsis are treated annually in US emergency departments (EDs).³ The Surviving Sepsis Campaign international consensus guidelines recommend protocol-driven treatment that uses quantitative resuscitation for ED patients with septic shock, underscoring the importance of early identification and treatment of these patients.⁴ Current consensus definition of septic shock requires suspicion of infection in the setting of either hypotension after fluid challenge or vasopressor requirement. However, some patients manifest global

tissue hypoxia, evidenced by an elevated blood lactate ≥ 4 mmol/L in the setting of normotension, a state sometimes referred to as cryptic shock.^{5–7}

Although elevated blood lactate has been previously shown to be a strong predictor of mortality in various critical care populations,^{8–10} we are aware of no study to date that has directly compared the outcomes of patients with severe sepsis who are treated with early quantitative resuscitation for cryptic shock versus overt shock. In this study we sought to compare outcomes of consecutive, prospectively collected patients presenting to three US EDs with severe sepsis and treated with an early quantitative resuscitation protocol for cryptic shock versus overt shock.

2. Methods

2.1. Study design

We conducted a preplanned secondary analysis of a recently completed prospective, parallel group, non-blinded randomized

[☆] A Spanish translated version of the summary of this article appears as Appendix in the final online version at doi:10.1016/j.resuscitation.2011.06.015.

* Corresponding author at: Department of Emergency Medicine, University of Mississippi Medical Center, 2500 N State Street, Jackson, MS 39216, United States.

E-mail address: aejones@umc.edu (A.E. Jones).




Fig. 1. Study flow diagram.

clinical trial designed to assess the non-inferiority of lactate clearance versus central venous oxygen saturation (ScvO₂) as the protocol endpoint that evaluated the adequacy of oxygen delivery during ED based early quantitative resuscitation of sepsis.¹¹ The trial was registered on Clinicaltrials.gov identifier NCT00372502.

The trial took place from January 2007 to January 2009 at Carolinas Medical Center, Charlotte, NC, Beth Israel Deaconess Medical Center, Boston, MA, and Cooper University Hospital, Camden, NJ, all of which are large, urban, tertiary care hospitals staffed by emergency medicine resident physicians supervised by board certified emergency medicine attending physicians. The study was approved by the Institutional Review Board at each institution (090602A) and all participants or their surrogate provided written informed consent for participation.

Consecutive patients presenting to one of the participating EDs with severe sepsis or septic shock were eligible for enrollment if they were older than 17 years, had confirmed or suspected infection, two or more systemic inflammatory response criteria,¹² and hypoperfusion evidenced by either a systolic blood pressure (SBP) lower than 90 mmHg after a minimum of 20 mL/kg rapid volume challenge or a blood lactate concentration of at least 4 mmol/L. The criteria for exclusion from the study were pregnancy, any primary diagnosis other than sep-

sis, suspected requirement for immediate surgery within 6 h of diagnosis, an absolute contraindication to chest or neck central venous catheterization, cardiopulmonary resuscitation, and advanced directive orders that would restrict the study procedure.

After enrollment patients were randomly assigned to 1 of 2 groups. Each group received structured quantitative resuscitation while in the ED (the resuscitation protocol can be found at: <http://jama.ama-assn.org/content/suppl/2010/02/18/303.8.739.DC1/jwe05013.02.24.2010.pdf>). The ScvO₂ group (N=150) was resuscitated by sequentially providing therapy needed to meet thresholds of central venous pressure, followed by mean arterial pressure, and then ScvO₂ as originally described by Rivers et al.¹³ The lactate clearance group (N=150) had similarly targeted thresholds in central venous pressure, followed by mean arterial pressure, and then lactate clearance (defined as a decrease in serum lactate of at least 10% over 2 h) instead of ScvO₂ to assess for adequate oxygen delivery. The study protocol was continued until all endpoints were achieved or a maximum of 6 h. The published results of this study showed a 6% (95% confidence intervals –3% to 14%) in-hospital mortality difference between the two study groups, confirming the primary hypothesis of non-inferiority.¹¹

2.2. Data analysis and outcomes

The primary outcome was in-hospital mortality. We compared outcomes data of patients who qualified for enrollment with cryptic shock, defined as a lactate >4 mmol/L and normotension (SBP at least 90 mmHg) to those that qualified with overt shock, defined as hypotension (SBP lower than 90 mmHg) after a minimum of 20 mL/kg rapid volume challenge with Kaplan–Meier survival estimates and generalized Wilcoxon (Peto–Prentice) log rank test. Baseline characteristics and co-interventions were compared using chi-square or Fisher exact tests for categorical data, and *t*-tests or Mann–Whitney–*U* tests for continuous data, as appropriate. Secondary outcomes included ICU and hospital length of stay and in-hospital complications.

Odds ratios (ORs) were calculated to determine independent predictors of in-hospital mortality by using logistic regression with bootstrap correction for 95% confidence intervals. Six variables (age, sequential organ failure assessment (SOFA) score, initial lactate, pulmonary infection, presence of end stage renal disease, and group assignment (overt or cryptic shock)) were entered into the regression analysis. Continuous data are presented as means and standard deviations or medians and interquartile ranges. Categorical data are presented as proportions with 95% confidence intervals (CIs). All statistical tests were two sided with *p* < 0.05 considered significant. All data were analyzed using StatsDirect statistical software (StatsDirect 2.7.7, Cheshire, England).

3. Results

A total of 300 subjects were enrolled, 53 in the cryptic shock group and 247 in the overt shock group (Fig. 1). Baseline demographics and baseline characteristics are shown in Table 1. Patients with diabetes mellitus, end-stage renal disease, and intra-abdominal infections were significantly more likely to present with cryptic shock. Blood cultures were positive in 115/300 (38%) of patients with 69/115 (60%) being gram positive organisms and 46/115 (40%) being gram negative organisms. Baseline physiological and severity of illness characteristics are shown in Table 2. As expected, patients in the cryptic shock group had a significantly higher baseline SBP and a significantly higher blood lactate concentration.

There were no differences in co-interventions administered between the cryptic and overt shock groups (Table 3). A total of 43% (23/53) of the patients in the cryptic shock group and 75% (184/247) of patients in the overt shock group required continuous vasopressor infusion at some point during the hospitalization. There was an equal proportion of subjects randomized to the interventional (lactate clearance) arm in both the cryptic shock (27/53, 51%) and overt shock (123/247, 50%) groups and there were no differences in the resuscitation goals achieved between the groups (Table 4).

The primary outcome of in-hospital mortality was observed in 11/53 (20%, 95% CI 11–34) of patients in the cryptic shock group compared with 48/247 (19%, 95% CI 15–25) in the overt shock group, difference of 1% (95% CI –10 to 14). Fig. 2 shows the Kaplan–Meier survival curve for the two groups. There was no significant difference in survival between the groups, log rank test *p* = 0.81. Additionally, we found no difference in ICU or hospital length of stay or complications between the groups (Table 5). The adjusted multiple logistic regression analysis results confirmed SOFA score as the only independent predictor of mortality (OR 1.1, 95% confidence interval 1.0–1.2). Of note, the logistic regression results support the results of our bivariate analysis by confirming that overt shock was not an independent predictor of mortality (OR 0.5, 95% confidence intervals 0.2–1.1). The model showed good fit, Hosmer–Lemeshow test *p* = 0.76.

Table 1
Patient demographics and clinical characteristics.

Variable	CS group (N = 53)	OS group (N = 247)	<i>p</i> value
Age ^a	65 (55,74)	61 (49,71)	0.14
Race (%)			
Caucasian	28 (53)	136 (55)	0.89
Black American	18 (34)	84 (34)	
Other	7 (13)	27 (11)	
Sex (%)			
Male	26 (49)	137 (55)	0.49
Female	27 (51)	110 (45)	
Co-morbidities (%)			
Diabetes mellitus	26 (49)	76 (31)	0.02
Chronic obstructive pulmonary disease	9 (17)	41 (17)	0.99
Human immunodeficiency virus	2 (4)	23 (21)	0.27
End stage renal disease	10 (19)	19 (8)	0.03
Active malignancy	13 (25)	61 (25)	0.99
Organ transplant	3 (6)	8 (3)	0.42
Indwelling vascular line	5 (9)	38 (15)	0.36
Nursing home resident	7 (13)	49 (20)	0.35
Do not resuscitate	2 (4)	7 (3)	0.66
Disease severity ^{a,b}			
SAPS II score	43 (32,54)	42 (31,55)	0.94
SOFA score	6 (4,9)	6 (4,9)	0.44
MEDS score	11 (9,12)	11 (8,14)	0.62
Suspected source of infection (%)			
Pulmonary	10 (19)	92 (37)	0.02
Urinary tract	13 (25)	66 (27)	
Intra-abdominal	16 (30)	33 (13)	
Skin/soft tissue	7 (13)	28 (11)	
Blood	1 (2)	10 (4)	
Unknown	6 (11)	18 (7)	

Abbreviations: CS, cryptic shock; OS, overt shock; SAPS, simple acute physiology score; SOFA, sequential organ failure assessment; MEDS, mortality in emergency department sepsis.

^a Median (IQR).

^b Disease severity scores calculated at time of enrollment.

Table 2
Physiological, severity of illness, and laboratory measurements.

Variable ^a	Initial value
Systolic blood pressure (mmHg)	
Cryptic shock group	108 (92, 126)
Overt shock group	85 (77, 98)
<i>p</i> value	<0.01
Heart rate (beats/min)	
Cryptic shock group	114 (91, 128)
Overt shock group	102 (85, 120)
<i>p</i> value	0.04
Central venous pressure (mmHg)	
Cryptic shock group	9 (5, 14)
Overt shock group	10 (7, 14)
<i>p</i> value	0.33
Central venous oxygen saturation (%)	
Cryptic shock group	79 (65, 84)
Overt shock group	78 (64, 87)
<i>p</i> value	0.67
Lactate level (mmol/L)	
Cryptic shock group	5.8 (4.5, 7.5)
Overt shock group	2.6 (1.4, 4.3)
<i>p</i> value	<0.01
Respiratory rate (breaths/min)	
Cryptic shock group	26 (20, 32)
Overt shock group	22 (18, 28)
<i>p</i> value	0.01
Glasgow coma scale	
Cryptic shock group	15 (13, 15)
Overt shock group	15 (14, 15)
<i>p</i> value	0.62


Abbreviations: mmHg, millimeters of mercury; min, minutes; mmol, millimoles; L, liter.

^a Median (IQR).

Table 3
Administered treatments and resuscitation endpoints.

Intervention	Value
Total crystalloid volume, 0–6 h (L) ^a	
CS group	4.0 (2.1, 5.6)
OS group	4.6 (2.8, 6.0)
p value	0.17
Corticosteroids, 0–6 h n (%)	
CS group	5 (9)
OS group	39 (16)
p value	0.33
Time to initial antibiotics (min) ^{a,b}	
CS group	116 (70, 162)
OS group	113 (62, 175)
p value	0.63
Mechanical ventilation n (%)	
CS group	19 (32)
OS group	77 (31)
p value	0.61
Activated protein C n (%)	
CS group	1 (2)
OS group	4 (2)
p value	0.99

Abbreviations: CS, cryptic shock; OS, overt shock; PRBC, packed red blood cell.

^a Median (IQR).^b Time from triage to initiation of antibiotics.**Fig. 2.** Kaplan–Meier survival curves for overt shock and cryptic shock groups.

4. Discussion

In this report we document the outcome of patients with cryptic septic shock who were treated with early quantitative resuscitation as compared to patients with overt septic shock. Our findings indicate that patients who qualify for early protocolized sepsis resuscitation with **cryptic shock, defined as a lactate measurement ≥ 4 mmol/L and SBP of at least 90 mmHg, have an in-hospital mortality rate (21%) that is not different than patients who qualify with overt shock (19%).** These data highlight the **need to screen patients for signs of occult hypoperfusion,** and given the high mortality

Table 4
Resuscitation goals achieved.

Goal	CS group (N = 53)	OS group (N = 247)	p value
Central venous pressure ≥ 8 mmHg (%)	49 (92)	220 (89)	0.46
Mean arterial pressure ≥ 65 mmHg (%)	50 (94)	233 (94)	0.99
Central venous oxygen saturation ≥ 70 (%) or lactate clearance ≥ 10 (%) ^a	51 (96)	237 (97)	0.69

Abbreviations: CS, cryptic shock; OS, overt shock; mmHg, millimeters of mercury.

^a Depending on protocol group assignment.**Table 5**
Hospital mortality and length of stay.

Variable	CS group (N = 53)	OS group (N = 247)	p value
In-hospital mortality (%) ^a	11 (21)	48 (19)	0.82
Length of stay ^b			
ICU	3.3 (2, 6.2)	3.0 (1.7, 6.5)	0.80
Hospital	8 (4.7, 14)	8 (5, 13.9)	0.84
Hospital complications (%)			
Multiple organ failure	15 (28)	54 (22)	0.41
Care withdrawn	9 (17)	28 (11)	0.39

Abbreviations: CS, cryptic shock; OS, overt shock; ICU, intensive care unit.

^a Primary study endpoint.^b Median (IQR).

rate associated with an **elevated serum lactate,** also suggest that patients with biochemical evidence of inadequate oxygen delivery **despite normal blood pressure should be included in early sepsis resuscitation pathways.**

Measurement of serum lactate is an accepted method of assessing for global tissue hypoxia, and its prognostic value in various populations has been described.^{9,14,15} Retrospective¹⁵ and prospective studies⁶ of heterogenous ED populations with suspected infection have suggested that **elevated serum lactate in the setting of normotension, or cryptic shock, carries a worse prognosis than a normal serum lactate.** The present study complements these previous investigations by documenting equivalent outcomes of patients with cryptic septic shock treated with early aggressive resuscitation as compared to patients with overt septic shock. It is important to note that a variety of lactate cutoffs have been reported in the literature as abnormal, and that dichotomizing the lactate into normal or abnormal may significantly reduce the predictive value of the test.¹⁵ However, for the purposes of this study, a **lactate of >4 mmol/L was considered the threshold for cryptic shock based on the original, and most commonly used inclusion criteria for early goal-directed therapy.**¹³

A clinician could dismiss an elevated serum lactate in the setting of hemodynamic stability as being a less acutely ill patient than one presenting with overt hypotension after volume challenge. This view may result in a tendency to withhold certain early interventions, such as early quantitative resuscitation. However, the clinical data from the present study **do not support a clear distinction between these two groups and most importantly, both have the same high risk of death.** We interpret these data to indicate that early, aggressive resuscitation protocols available for patients in overt shock should be strongly considered for patients in cryptic shock.

One of the strengths of our study is that both groups were treated with an early aggressive resuscitation protocol targeting physiological endpoints, which is an important difference between this study and previous cohort studies on this topic.^{6,15} Additionally, in a general sense enrollment in a controlled clinical trial with specific inclusion criteria results in a more homogenous patient population than might be seen in registries or observational studies. Thus our study enhances the current literature by demonstrating that patients presenting to the ED with severe sepsis who are identified as candidates for and are treated with an early quantitative resuscitation protocol, inclusion by elevation of serum lactate of at

least 4.0 mmol/L with normotension carries an equal risk of hospital death as overt shock, despite equally aggressive therapy.

This report has several limitations that should be noted. First, although we had robust mechanisms at each center to ensure as close to a consecutive sample as was possible, it remains possible that some of the patients with elevated lactate were not enrolled. Second, this study was conducted at institutions that had established ED based quantitative resuscitation programs for sepsis prior to initiation of the study.^{16–18} Therefore, our results may not be generalizable to centers that do not routinely perform early quantitative resuscitation. Third, in the parent study patients were enrolled into one of two treatment protocols, which could potentially affect outcome. However, in the present analysis there were an equal proportion of patients in the cryptic shock and overt shock groups that were assigned to each treatment group and achievement of resuscitation goals were similar in both the overt and cryptic shock groups. Therefore we do not suspect significant interaction between the trial treatment and the shock group.

5. Conclusion

In this analysis, we document that patients presenting with cryptic septic shock have a mortality rate that is not significantly different from that of overt septic shock. These data suggest the need for early aggressive screening and treatment of patients with evidence of global tissue hypoxia in the absence of hypotension.

Conflict of interest statement

None of the authors have any conflicts of interests to report.

Acknowledgements

This work was supported by grant K23GM076652 (Jones) from the National Institute of General Medical Sciences/National Institutes of Health. Dr Puskarich has salary support by grant 10POST3560001 from the American Heart Association. Dr. Trzeciak is supported by grant GM083211 from the National Institute of General Medical Sciences/National Institutes of Health. Dr Shapiro was supported by grants HL091757 and GM076659 from the NIH. The

sponsors had no role in the collection, analysis, or interpretation of the study data, nor in the writing of the manuscript.

References

1. Angus D, Linde-Zwirble W, Lidicker J, Clermont G, Carcillo J, Pinsky M. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 2001;29:1303–10.
2. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. *Crit Care Med* 2007;35:1244–50.
3. Wang HE, Shapiro NI, Angus DC, Yealy DM. National estimates of severe sepsis in United States emergency departments. *Crit Care Med* 2007;35:1928–36.
4. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. *Crit Care Med* 2008;36:296–327.
5. Donnino MW, Nguyen B, Jacobsen G, Tomianovich M, Rivers E. Cryptic septic shock: a sub-analysis of early, goal-directed therapy. *Chest* 2003;124:90S–190S.
6. Howell MD, Donnino M, Clardy P, Talmor D, Shapiro NI. Occult hypoperfusion and mortality in patients with suspected infection. *Intensive Care Med* 2007;33:1892–9.
7. Trzeciak S. Lac-time? *Crit Care Med* 2004;32:1785–6.
8. Henning R, Weil M, Weiner F. Blood lactate as a prognostic indicator of survival in patients with acute myocardial infarction. *Circ Shock* 1982;9:307–15.
9. Abramson D, Scalea T, Hitchcock R, Trooskin S, Henry S, Greenspan J. Lactate clearance and survival following injury. *J Trauma* 1993;35:584–9.
10. Shapiro NI, Howell MD, Talmor D, et al. Serum lactate as a predictor of mortality in emergency department patients with infection. *Ann Emerg Med* 2005;45:524–8.
11. Jones AE, Shapiro NI, Trzeciak S, et al. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. *JAMA* 2010;303:739–46.
12. Bone R, Balk R, Cerra F, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest* 1992;101:1644–55.
13. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med* 2001;345:1368–77.
14. Bernardin G, Pradler C, Tiger F, Deloffre P, Mattei M. Blood pressure and arterial lactate level are early indicators of short-term survival in human septic shock. *Intensive Care Med* 1996;22:17–25.
15. Mikkelsen M, Miliades A, Gaieski D, et al. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. *Crit Care Med* 2009;37:1670–7.
16. Jones AE, Focht A, Horton JM, Kline JA. Prospective external validation of the clinical effectiveness of an emergency department-based early goal directed therapy protocol for severe sepsis and septic shock. *Chest* 2007;132:425–32.
17. Trzeciak S, Dellinger RP, Abata NL, et al. Translating research to clinical practice: a 1-year experience with implementing early goal-directed therapy for septic shock in the emergency department. *Chest* 2006;129:225–35.
18. Shapiro NI, Howell MD, Talmor D, et al. Implementation and outcomes of the Multiple Urgent Sepsis Therapies (MUST) protocol. *Crit Care Med* 2006;34:1025–32.